MedTrace Logo

The Detection of Circulating Tumor Cells (CTCs) in Patients With Prostatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment

NCT02450435 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2015-12-30

No results posted yet for this study

Summary

Circulating tumor cells (CTCs) have the potential to provide a surrogate for'real-time biopsy' of tumor biological activity. Enumeration and molecular characterization of CTCs in prostatic cancer could play an important role in diagnosis, predicting the risk for tumor recurrence, and providing novel target therapy biomarkers. In view of these facts, the investigators wanted to demonstrate the value of multiparameter flow cytometry in detecting human tumor cells of prostatic cancer in normal peripheral blood after cryosurgery with or without dendritic cell(DC)-cytokine-induced killers(CIK) treatment, and the investigators also compared the specificity with reverse transcriptase polymerase chain reaction (RT-PCR) method.

Conditions

  • Neoplastic Cells, Circulating

Interventions

OTHER

Flow cytometry (FCM)

Use FCM to test PBMCs/CTCs from volunteers/patients.

OTHER

RT-PCR

Use RT-PCR to test PBMCs/CTCs from volunteers/patients.

Sponsors & Collaborators

  • Fuda Cancer Hospital, Guangzhou

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02450435 on ClinicalTrials.gov